financetom
Business
financetom
/
Business
/
Utility ALLETE's Q3 profit falls on lower sales to industrial customers
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Utility ALLETE's Q3 profit falls on lower sales to industrial customers
Oct 31, 2025 3:49 AM

Overview

* ALLETE Q3 2025 earnings per share fell to 46 cents from 78 cents last year

* Company awaits MPUC order to complete partnership with CPP Investments and GIP

* ALLETE Clean Energy Q3 net loss due to transmission network outages in SPP market

Outlook

* ALLETE ( ALE ) expects lower sales to industrial customers to continue through 2025

* Company anticipates $200 mln in benefits for Minnesota Power customers

* Rate case stay-out provision to impact 2026 financials

Result Drivers

* INDUSTRIAL SALES DECLINE - Lower sales to industrial customers at Minnesota Power impacted net income negatively

* TRANSMISSION OUTAGES - ALLETE Clean Energy's net loss due to transmission network outages in the SPP market affecting production and tax credits

* PROJECT CLOSING TIMING - New Energy Equity's lower net income due to timing of renewable project closings, partially offset by higher tax equity earnings

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $375 mln

Operatin

g

revenue

Q3 Net $13.30

Income mln

Q3 Basic $0.47

EPS

Q3 $29.60

Operatin mln

g Income

Q3 $14.90

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the electric utilities peer group is "buy"

* Wall Street's median 12-month price target for ALLETE Inc ( ALE ) is $67.86, about 0.7% above its October 30 closing price of $67.39

* The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 16 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
DocGo's Cardiac RMS Unit Signs Contract With Mississippi Hospital System
DocGo's Cardiac RMS Unit Signs Contract With Mississippi Hospital System
Dec 4, 2024
09:48 AM EST, 12/04/2024 (MT Newswires) -- DocGo ( DCGO ) said Wednesday that its Cardiac RMS subsidiary has signed a contract with an unnamed hospital system in Mississippi. Under the deal, DocGo's ( DCGO ) Cardiac RMS is scheduled to begin remote monitoring for nearly 3,000 patients with cardiac implantable electronic devices in early 2025. Financial terms were not...
Super Micro Computer Unusual Options Activity For December 04
Super Micro Computer Unusual Options Activity For December 04
Dec 4, 2024
Investors with a lot of money to spend have taken a bullish stance on Super Micro Computer ( SMCI ) . And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something...
Eli Lilly's Zepbound Vs. Novo Nordisk's Wegovy - Which Shows Greater Weight Loss?
Eli Lilly's Zepbound Vs. Novo Nordisk's Wegovy - Which Shows Greater Weight Loss?
Dec 4, 2024
On Wednesday, Eli Lilly And Co ( LLY ) revealed topline data from the SURMOUNT-5 phase 3b trial evaluating the efficacy and safety of Zepbound (tirzepatide) compared with Novo Nordisk A/S’ Wegovy (semaglutide) in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes.  Zepbound provided a 47%...
Altair Engineering Collaborating With Auburn University to Develop Analytical Models for Cyclonic Flows
Altair Engineering Collaborating With Auburn University to Develop Analytical Models for Cyclonic Flows
Dec 4, 2024
09:53 AM EST, 12/04/2024 (MT Newswires) -- Altair Engineering ( ALTR ) said Wednesday that it is partnering with Auburn University to develop analytical models for cyclonic flows under a roughly $1.3 million phase II STTR contract awarded by the US Department of Air Force's AFWERX arm. The parties will also construct computational models, and evaluate various vortex engines to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved